Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
AKTSthis companyAktis Oncology, Inc.	$16.11	-18.82×	-8.05×	181.08×	-18.73×	-78.3%	100.0%	-1149.5%	-980.9%	43.6%	-31.8%	-6.3%	-0.08×	0.43×	0×	7.37×	0.0%	2	6.57	2	C
AKTXAkari Therapeutics, Plc	$7.49	-0×	0.01×	0×	0.24×	-6.5%	0.0%	0.0%	0.0%	-61.1%	-45.0%	-4345.0%	0.03×	0.26×	-18.2×	0.44×	0.0%	2	-12.64	2	B-
AURAAura Biosciences, Inc.	$7.24	-3.1×	2.4×	0×	-2.73×	-88.8%	0.0%	0.0%	0.0%	-77.6%	-73.1%	-25.9%	0.13×	0.4×	0×	8.15×	0.0%	2	8.97	2	C+
IMNMImmunome, Inc.	$19.48	-8.84×	2.96×	270.32×	-5.86×	-62.3%	57.4%	-3084.8%	-3060.0%	-33.5%	-33.5%	-10.7%	0.01×	3.1×	0×	14.69×	0.0%	2	31.88	2	C+
MGNXMacroGenics, Inc.	$2.44	-1.36×	1.83×	0.68×	-2.54×	-2714.5%	71.1%	-48.7%	-49.9%	-134.2%	-33.0%	-81.6%	1.92×	-0.83×	-8.56×	5.1×	0.0%	1	-4.43	1	D+
Peer median	—	-2.23×	2.12×	0.34×	-2.63×	-75.6%	28.7%	-24.4%	-25.0%	-69.3%	-39.3%	-53.7%	0.08×	0.33×	-4.28×	6.62×	0.0%	2	2.27	2	—